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The natural product carolacton is a macrolide keto-carboxylic acid produced by the myx-
obacterium Sorangium cellulosum, and was originally described as an antibacterial compound.
Here we show that carolacton targets FolD, a key enzyme from the folate-dependent C1
metabolism. We characterize the interaction between bacterial FolD and carolacton bio-
physically, structurally and biochemically. Carolacton binds FolD with nanomolar affinity, and
the crystal structure of the FolD–carolacton complex reveals the mode of binding. We show
that the human FolD orthologs, MTHFD1 and MTHFD2, are also inhibited in the low nM
range, and that micromolar concentrations of carolacton inhibit the growth of cancer cell
lines. As mitochondrial MTHFD2 is known to be upregulated in cancer cells, it may be
possible to use carolacton as an inhibitor tool compound to assess MTHFD2 as an anti-
cancer target.
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Natural products have served as a source of novel drugleads for thousands of years, but for many of them theirmechanism of action (MoA) remains unknown1. The
secondary metabolite carolacton is a macrolide keto-carboxylic
acid produced by the myxobacterium Sorangium cellulosum with
an elusive molecular target2. Carolacton is a potent inhibitor of
biofilm formation in the human pathogen Streptococcus mutans
and a growth inhibitor of S. pneumoniae3. It also inhibits the
efflux pump mutant Escherichia coliΔtolC2, 4. Carolacton has
moderate activity on various fungi but showed no acute toxicity
to L929 mouse cells2, 4. Although carolacton seemed to be a very
narrow spectrum antibiotic, its interesting anti-biofilm and anti-
fungal activity aroused our interest, and we aimed to uncover its
MoA.
Here we report the identification and validation of FolD as the
carolacton target in E. coliΔtolC and streptococci. FolD occupies a
central position in the folate-dependent C1 metabolism. Folate
(vitamin B9) is an essential co-factor in all cells, but it is syn-
thesized only by bacteria and plants5. The folate-dependent C1
metabolism is highly conserved in all domains of life and it
provides the key building blocks for growth, most importantly
nucleic acids, amino acids, provitamines and formylated
methionine tRNA for translation initiation6. FolD is a dual
function enzyme: it catalyses a reversible NADP+-dependent
dehydrogenation step (5,10-methylenetetrahydrofolate (5,10-
CH2-THF) dehydrogenase (DH)) and a subsequent cyclohy-
drolysis step (5,10-methenyltetrahydrofolate (5,10-CH=THF)
cyclohydrolase (CYH)) (Fig. 1)7. We demonstrate that carolacton
inhibits both reactions catalyzed by FolD at nM concentrations.
Determination of the FolD/carolacton complex crystal structure
allows us to rationalize how mutations in FolD can confer
resistance to carolacton.
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Fig. 1 The enzymatic routes to synthesize 10-CHO-THF in different organisms. In E. coli, 10-CHO-THF is synthesized by FolD, while in several other bacteria
such as Streptococci, 10-CHO-THF can be produced via an alternative enzyme named Fhs. In humans, there are different enzymes in the cytoplasm and the
mitochondrion. In the cytoplasm, MTHFD1, which is a tri-functional enzyme, exerts FolD-DH, FolD-CYH and Fhs functions. In the mitochondrion, while
MTHFD2 and MTHFD2L have FolD functions, MTHFD1L plays the same role as Fhs. The chemical structure of FolD inhibitor carolacton is shown in the
centre
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Higher organisms such as humans also possess FolD orthologs:
the cytosolic trifunctional protein MTHFD1, which has DH and
CYH, but also a formate tetrahydrofolate synthase (Fhs) domain,
maintains the metabolism of methylene-, methenyl- and formyl-
THF (10-CHO-THF)8–10. In mitochondria, the DH and CYH
activities are provided by the FolD analogues MTHFD2 and
MTHFD2L (Fig. 1)9, 10. The enzymes involved in folate-
dependent C1 metabolism, therefore, represent powerful targets
for the inhibition of fast growing cells and have been targeted by
anticancer drugs such as clinically used methotrexate, which
inhibits dihydrofolate reductase11. Because of its central role in
the C1 metabolism, FolD was the subject of numerous studies:
Although synthetic folate-analogue inhibitors were found that
strongly inhibited FolD in vitro, none were active on whole
bacterial cells12–15. Several studies have reported inhibitors of the
FolD analogues MTHFD1 or MTHFD2, some of which display
in vivo activity against human cells15–17. However, either poor
activity was observed (e.g. LY345899, IC50 128 μM) or the com-
pounds were unspecific (e.g. LY231514, which principally inhibits
thymidylate synthase) (Supplementary Fig. 1)16, 18, 19.
To gauge carolacton’s potential for inhibiting the human FolD
variants, we test it against the two human FolD orthologs,
MTHFD1 and MTHFD2, which are also inhibited in the low nM
range. When we tested carolacton’s effects on a panel of human
cell lines, we observed activity in the µM range. Since MTHFD2 is
differentially upregulated in cancer tissue, it presents an attractive
target for anti-cancer compounds. We believe that carolacton, a
non-substrate inhibitor, may be used as a tool compound to
assess MTHFD2 as an anti-cancer target20, 21.
Results
FolD is the carolacton target. To facilitate the identification of
the molecular target of carolacton, E. coliΔtolC (E. coli without
outer membrane efflux protein TolC) was chosen to develop
carolacton-resistant mutants. After 1 week, carolacton-resistant
mutants arose spontaneously on agar plates supplemented with
four times the carolacton minimum inhibitory concentration
(MIC= 0.125 μg/mL). Whole-genome sequencing of five inde-
pendent mutants unveiled that only the gene encoding FolD was
mutated (Supplementary Tables 1 and 2). Four different muta-
tions conferring resistance were identified: G8S (observed in two
mutants), K54N, Q98H and K54_K56delinsK (hereafter referred
to as ΔK54R55) (Supplementary Figs. 2 and 3). To validate FolD
as the carolacton target and to understand the potential MoA, E.
coliΔtolC FolD (ecFolD) was overexpressed and purified. A SDS-
PAGE of all proteins used in this study, as well as their LC-MS
analysis, can be found in Supplementary Fig. 4. The purified
ecFolD showed DH and CYH activity comparable to previously
reported bacterial FolDs13, 22, 23, including the DH activity of E.
coli FolD24. DH and CYH activities were found to be much
stronger than reported for ecFolD in two other studies25, 26
(Supplementary Table 3). This discrepancy has been noted by
other authors and possible reasons include impurities24, 26 and
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Fig. 2 Carolacton is a potent and tightly binding inhibitor of FolD. a IC50 determination for carolacton against DH and CYH activities of ecFolD. Data are
presented as means± s.e.m of three independent replicates. IC50s were obtained via logistic dose–response fitting. The one-way ANOVA test was used for
statistical analysis, P< 0.01. b SPR analysis of carolacton binding to ecFolD, RU resonance units. Carolacton shows strong binding to ecFolD. The estimated
KD was obtained by fitting the association and dissociation signals with a 1:1 interacton model using the Biacore X100 Evaluation Software. c Top view of the
FolD–carolacton complex structure. Cartoon representations of apo-FolD (gold) and FolD in complex with carolacton (blue, lime) are superposed to show
the movement and partial dissolution of helix α2. Residues involved in carolacton binding are shown as sticks. The difference electron density (Fo−Fc)
contoured to 3σ with phases calculated from a model that was refined in the absence of carolacton is shown as a grey isomesh. d Surface representation of
FolD bound to carolacton, side-view. Colours correspond to c. Partial dissolution of helix α2 as a result of the interaction of Y50, which forms a lid on
carolacton that is further stabilized by R234, can be seen
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excessive enzyme concentrations used for enzyme kinetics25.
When carolacton was added to the reaction, we observed strong
inhibition of both steps catalysed by ecFolD (DH and CYH) in a
carolacton concentration-dependent manner (Fig. 2a). Car-
olacton also showed competitive inhibition with both substrates
and the cofactor involved in DH and CYH catalytic steps, which
were 5,10-CH2-THF (Ki= 21 nM), NADP+ (Ki= 11 nM) and
5,10-CH=THF (Ki= 32 nM) (Supplementary Table 4), as the
apparent Michaelis constant (KM) increased when carolacton was
added (Supplementary Fig. 5). These findings supported that
ecFolD is indeed the target of carolacton. To confirm that both
molecules interact, we then tested ecFolD for its ability to bind
carolacton using surface plasmon resonance (SPR). The observed
interaction between ecFolD and carolacton was very strong (KD
= 10 nM), further confirming ecFolD as the carolacton target
(Fig. 2b and Supplementary Table 5).
The structure of the ecFolD–carolacton complex. To under-
stand how carolacton binds to ecFolD and thus rationalize the
mutations giving rise to carolacton resistance, we determined the
crystal structure of ecFolD in complex with carolacton. The ori-
ginally reported crystallization conditions for ecFolD27 yielded
only poorly diffracting crystals in our hands. Reductive lysine
methylation ecFolDMeth gave a new crystal form that diffracted
well. Since a key active-site residue of ecFolD is a lysine (K54)15,
and we found that mutations at this position conferred carolacton
resistance (see resistant mutants above), we thought that K54
could be involved in carolacton binding, and thus sought to
protect this residue from methylation. To this end, we incubated
ecFolD with an excess of carolacton before lysine methylation.
After the reaction, carolacton was removed via size exclusion
chromatography and the resultant ecFolDMeth tested for activity.
We observed only a slight decrease in enzyme activity (Supple-
mentary Fig. 6a) and no significant change of carolacton’s ability
to inhibit ecFolD DH activity (Supplementary Fig. 6b). To further
analyse whether we had methylated active-site K54, we first
determined the apo-structure of ecFolDMeth. The protein crys-
tallized in space group P21 and crystals diffracted to 1.9 Å reso-
lution (PDB ID 5o28). Full data collection and refinement
statistics for all structures can be found in Supplementary Table 6.
ecFolDMeth showed the canonical dimeric arrangement observed
in the structures of ecFolD (PDB ID 1B0A)27 and its orthologs17,
28 and the overall structure was virtually unchanged when com-
pared to unmethylated protein (Supplementary Fig. 7). We
observed unambiguous electron density for methylated lysines at
positions K4, 22, 194, 212 and 222. With the exception of K22, all
of them can be found at crystal contacts (Supplementary Fig. 8).
We observed density for unmethylated active-site K54, support-
ing our biochemical data that indicated this lysine was not
methylated (Supplementary Figs. 6 and 8). We soaked the apo
crystals of ecFolDMeth with 2 mM carolacton and harvested them
after 16 h. The soaked crystals diffracted to 2.1 Å (PDB ID 5o22)
and showed strong additional density at the protein’s active site in
three of the four monomers of the asymmetric unit (protomers A,
B and D, the picture in protomer C is skewed due to a crystal
contact). Carolacton can be fitted into the additional density
(Fig. 2c) and refines well (Supplementary Fig. 8). Binding of
carolacton to FolD has a minimal impact on FolD’s overall
structure (Cα rmsd 0.27 Å) and is facilitated by three hydrogen
bonds (K54 ε-amino group with carolacton O8 and O33 and
G261 main chain N with carolacton O29) and several hydro-
phobic interactions (Y50, I170, I232, P260, P265 and V268)
(Fig. 2c, d and Supplementary Fig. 9). The hydrophobic inter-
action between carolacton and Y50 causes a partial disruption of
helix α2 (residues 45–56) and allows the Y50 hydroxyl group to
form a hydrogen bond with the side-chain of R234 (Fig. 2d).
When carolacton is bound, the N-terminal residues of α2 and a
part of the loop connecting β1 with α2 (residues 41–44) become
disordered (residues 44–49). It has been noted by others that this
part of FolD is unstable15, 17, and we observe only poor density
for residues 44–56 in the ecFolDMeth apo structure (protomers A,
B and D; protomer C behaves differently due to a crystal contact).
We believe that this reflects a catalytic mechanism, in which a
meta-stable helix (α2) harbours a residue essential for catalysis.
Upon substrate (or carolacton) binding, Y50 engages in hydro-
phobic contact that completely destabilizes residues 44–49, while
the other half of the helix is stabilized (residues 50–56) (Fig. 2d).
When the FolD–carolacton complex structure is superposed
onto the human ortholog of FolD (PDB ID 1DIA), which was co-
crystallized with NADP+, and substrate analogue LY249543, it
can be seen that carolacton is likely to prevent binding of both co-
factor and substrates (Supplementary Fig. 10a, b). In a recent
study, a number of carolacton analogues were synthesized and
tested for their effects on S. mutans biofilm formation. None of
the reported compounds had improved bioactivity29. We
modelled the best-performing compound (‘carylacton’, see
structure in Supplementary Fig. 1) based on our complex
structure and discovered that carylacton would be able to form
better hydrophobic interactions with Y50 than carolacton. The
length of the carylacton tail, however, is one methylene group too
long to allow hydrogen bonding of the carboxy terminus with
G261 (Supplementary Fig. 10c). Our complex structure should
therefore help future synthetic efforts.
Effects of mutations on ecFolD and carolacton binding. The
effects of mutations K54N and G8S on carolacton binding can
easily be explained by the complex crystal structure. K54 provides
two hydrogen bonds to anchor carolacton in the active site of
ecFolD (Fig. 2c) and its mutation to N will severely affect the
binding of carolacton to ecFolD. G8 is not in direct contact with
carolacton, but its position and orientation in FolD implies that
the addition of any side-chain will cause a clash with C-terminal
helix α11 (Supplementary Fig. 11). G261, which forms a hydro-
gen bond with carolacton, is part of this helix and we assume that
the resulting movement of helix α11 leads to a clash with the
carboxyl group of carolacton. Due to the very tight fit of car-
olacton in this area, the clash cannot be remedied, but instead
leads to severely reduced binding of carolacton to ecFolD. Helix
α2 is vital for binding of carolacton to FolD since it contains both
K54 and Y50. It was therefore not unexpected that the deletion of
two residues from this helix (mutant ecFolDΔK54R55) severely
affected binding of carolacton to FolD. The final mutation, Q98H,
could not be rationalized using the complex structure and we
wondered if this mutation does in fact affect binding of car-
olacton to ecFolD or is an experimental artefact.
To test experimentally the effects of the mutations that we
discovered in carolacton resistant E. coli ΔtolC, we expressed and
purified all four mutant proteins: ecFolDG8S, ecFolDK54N,
ecFolDΔK54R55 and ecFolDQ98H. When we tested the mutants
for DH activity, we found that all of them were attenuated, but
with varying severity. The mutant K54N still retains ~19% of the
wild-type (wt) DH activity, but ΔK54R55 has only ~1% DH
activity left. The two-residue deletion might severely change the
NADP+ binding, which can be deduced from the dramatically
increased KM of NADP+. The DH activity of G8S and Q98H is
about 21 and 8% of the wt, respectively (Fig. 3a and
Supplementary Table 7).
Mutants K54N and ΔK54R55 showed no detectable CYH
activity, suggesting that K54 is essential for this reaction. The
kinetic properties of the CYH activity of mutants G8S and Q98H
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were not investigated since only very low CYH activity was
detected. We estimate residual activity of ~1% based on the
requirement to increase the enzyme concentration ~100-fold to
achieve wt turnover (Supplementary Fig. 12). The mutant E. coli
ΔtolC strains likely survive without CYH activity because the
turnover of 5,10-CH=THF to 10-CHO-THF can occur sponta-
neously30. These biochemical results are consistent with the
growth curves measured for these carolacton-resistant E. coli
ΔtolC strains: the one bearing ΔK54R55 mutation is the poorest
growing mutant. The K54N mutant strain also grows very slowly
even though its DH activity is not impaired as much as in
the ΔK54R55 mutant, which might be due to the total loss of
CYH activity (Supplementary Fig. 13).
The mutants G8S and Q98H could still be inhibited by
carolacton, but with much higher IC50 compared to the wt
(Fig. 3b and Supplementary Table 8). The central role of K54 is
highlighted by the fact that the residual DH activity of K54N and
ΔK54R55 is completely insensitive to carolacton (Fig. 3b), in
accordance with the SPR data that indicated that carolacton does
not bind to K54N (Supplementary Fig. 14a). It appears that,
under selection pressure, viable mutants had sacrificed CYH
activity (reaction can be spontaneous), but required retention of
FolD’s DH activity since no alternative pathway exists in E. coli31.
The binding of carolacton to ecFolD Q98H was seriously
attenuated as reflected by the SPR data (Supplementary Fig. 14b,
c). To understand how the mutation Q98H affects the binding of
carolacton, we determined the crystal structure of this mutant
(PDB ID 5o2a). After lysine methylation, this protein crystallized
in the same space group as the wt protein and crystals diffracted
to 1.9 Å. The overall structure of ecFolDMethQ98H is not altered
when compared to wt as a result of the mutation (Cα rmsd 0.11
Å) and the effect of the Q98H mutation was unexpected. The
presence of H98 allows the side-chain of Y50 to rotate 90°
compared to the apo wt ecFolD structure. It appears that in the wt
protein, Q98 helps to position the side-chain of Y50 such that it
can easily rotate to engage in hydrophobic interactions with
carolacton (or substrate) upon binding. In Q98H, the side-chain
of Y50 is able to rotate farther from the active site and packs
against residues V38, L40, L96 and H98. The result is a fully
ordered helix α2 with good density for all residues, which we
believe reflects a stabilization of the protein. The absence of the
hydrophobic interaction between carolacton and Y50 leads to
significantly weakened binding, which we believe to be reflected
by the much faster association and dissociation of carolacton in
SPR experiments with ecFolDQ98H (Fig. 3c, d, Supplementary
Fig. 14b and Supplementary Table 5).
Effects of carolacton on S. pneumoniae FolD. Carolacton was
originally discovered as an anti-streptococcal compound2, 4, and
the FolD ortholog from S. pneumoniae (spFolD) shares 49%
sequence identity with ecFolD. The key residues involved in
carolacton binding are conserved, and carolacton binds tightly to
spFolD (KD= 27 nM) (Supplementary Fig. 14d and Supplemen-
tary Table 5). Carolacton also showed competitive inhibition of
spFolD with slightly higher inhibition constants than ecFolD,
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as means± s.e.m of three independent replicates. DH specific activities were calculated based on the Vmax obtained via Michaelis–Menten fitting. The one-
way ANOVA test was used for statistical analysis, P< 0.01. b IC50 determination for carolacton against the DH activity of ecFolD and mutants. Data are
presented as means± s.e.m of three independent replicates. IC50s were obtained via logistic dose–response fitting. The one-way ANOVA test was used for
statistical analysis, P< 0.01. c Position of Y50 in ecFolDQ98H (gold). The position of Q98 in the apo (grey) and complex (blue) structures prevents the
side-chain of Y50 from rotating out of position. d Position of Y50 in the apo (grey), complex (blue) and Q98H (gold) structures. The 90° rotation of Y50 in
the Q98H mutant prevents Y50 from forming the hydrophobic lid on carolacton (lime sticks)
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which were still in the low nM range (Supplementary Figs. 15 and
16 and Supplementary Tables 4 and 8). Analysis of the inhibition
of FolD in streptococci is complicated by the fact that they, unlike
E. coli, possess an alternative route for one-carbon metabolism via
Fhs (Fig. 1)31, 32.
Effects of carolacton on the human FolD orthologs. As men-
tioned above, FolD orthologs are also present in humans. The
human enzymes hsMTHFD1_DC and hsMTHFD2 both share
42% sequence identity to ecFolD. The key residues involved in
carolacton binding are fully conserved (Supplementary Fig. 3),
and the structures of hsMTHFD1_DC and hsMTHFD2 are
conserved well when compared to ecFolD (pairwise Cα rmsds of
1.09 and 0.84 Å, respectively, Supplementary Fig. 17). We were
therefore confident that carolacton could also serve as an inhi-
bitor of the human enzymes. This would be of particular interest
since the mitochondrial hsMTHFD2 is overexpressed in many
tumor cells and thus its inhibition might cause a selective effect
on tumor growth20. We therefore expressed and purified
hsMTHFD1_DC and hsMTHFD2 to investigate them bio-
chemically. Not surprisingly, their inhibition by carolacton was
similar to that observed for ecFolD (Fig. 4a and Supplementary
Fig. 15). The Ki of carolacton against all three substrates and the
cofactor were also determined and are in the same range as those
for ecFolD (Supplementary Fig. 18 and Supplementary Tables 4
and 8). When the binding of carolacton to hsMTHFD2 was
analysed by SPR, we found strong binding on par with the
bacterial proteins (KD= 19 nM) (Fig. 4b and Supplementary
Table 5).
Carolacton is active against human cancer cell lines. Since the
human FolD orthologs are strongly inhibited by carolacton, we
were curious to see if carolacton would show activity on human
cancer cell lines. When tested against HCT-116, KB-3.1 and KB-
V.1 cells, carolacton displayed an EC50 of 25, 11 and 42 µM,
respectively. In each case, the maximum inhibition of cell growth
was >80%. The inhibition of human epidermoid carcinoma KB-
3.1 cells by carolacton is four times stronger than that of the
corresponding multidrug-resistant (MDR) cell line KB-V.1
(Table 1). In the latter cell line, the mdr1 gene is amplified, which
encodes the drug transporter P-glycoprotein (Pgp); this suggests
that Pgp may export carolacton from the cells. In the case of U-
937 cells, carolacton displayed no activity at concentrations up to
100 µM. However, when this cell line is grown in folate-depleted
medium, an EC50 of 42 µM and a maximum inhibition of 70% are
observed. This apparent folate-dependent activity on U-937 cells
supports that human FolD orthologs are the cellular targets of
carolacton in human cancer cells.
Efflux hampers carolacton activity. Carolacton shows no activity
against wt E. coli, but is highly active against efflux protein-
deficient E. coli ΔtolC. It also showed a four-fold decrease in
activity against Pgp-overexpressing KB-V.1 cells, in comparison
with KB-3.1 cells. To probe the role of efflux on carolacton’s
cellular activity, we treated E. coli DSM-1116 (wt) and E. coli
ΔtolC with a permeability enhancer and/or an efflux pump
inhibitor (Table 2). When E. coli DSM-1116 was treated with a
combination of carolacton and sub-inhibitory concentrations of
polymyxin B nonapaptide (PMBN) to increase outer membrane
permeability33, the MIC was still at the upmost range of the assay
(at least 64 µg/mL). The same assay repeated with carolacton-
susceptible E. coli ΔtolC showed a four-fold increase of carolacton
activity. In contrast, when E. coli DSM-1116 was treated with
carolacton and the efflux inhibitor phenylalanine–arginine β-
naphthylamide (PAβN)34, the carolacton MIC decreased to 2 μg/
mL. In addition, combining PMBN, carolacton and PAβN did not
enhance the effect of carolacton further. These data support that
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Fig. 4 Carolacton effects on the human enzyme hsMTHFD2. a IC50
determination for carolacton against DH and CYH activity of hsMTHFD2.
Data are presented as means± s.e.m. of three independent replicates. IC50s
were obtained via logistic dose–response fitting. The one-way ANOVA test
was used for statistical analysis, P< 0.01. b SPR analysis of carolacton
binding to hsMTHFD2. Carolacton shows strong binding to hsMTHFD2.
The estimated KD was obtained by fitting the association and dissociation
signals with a 1:1 interacton model using the Biacore X 100 Evaluation
Software
Table 1 EC50 values of carolacton on human cancer cell lines
Cell line EC50 (µM) Maximum inhibition
HCT-116 24.6± 0.8 >80%
KB-3.1 11.3± 3.6 >80%
KB-V.1 41.8± 14.5 >80%
U-937 >100 n.a.
U-937 (folate-depleted) 41.7± 15.2 65–75%
Table 2 MIC of carolacton on Escherichia coli determined in
cation-adjusted Mueller–Hinton broth
MIC (µg/mL)
E. coli (TolC-deficient) 0.13
E. coli (TolC-deficient) + PMBNa ≤0.03
E. coli DSM-1116 (WT) >64
E. coli DSM-1116 (WT) + PMBNa 64 to >64
E. coli DSM-1116 (WT) + PAβNb 2c
E. coli DSM-1116 (WT) + PMBNa + PAβNb 2c
a + 3 µg/mL polymyxin B nonapaptide (PMBN) for permeabilization
b + 20 µg/mL phenylalanine-arginine β-naphthylamide (PAβN; efflux inhibitor)
c No full inhibition
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carolacton can enter cells, but it is excreted by efflux proteins,
which seems to be the main challenge to be addressed when
attempting to increase the cellular activity of carolacton.
Discussion
We have identified the bifunctional enzyme FolD from the folate-
dependent C1 metabolism as the target of carolacton. Through
the analyses of carolacton-resistant E. coli ΔtolC mutants, bio-
chemical experiments and the crystal structure of the FolD-
carolacton complex, we were able to identify the key residues
involved in carolacton binding (Y50, K54, and G261). All the
residues mutated in carolacton-resistant E. coli ΔtolC isolates
affected FolD’s DH activity only partially, but almost completely
abolished its CYH activity. This reflects the fact that the DH
activity is vital (no alternative pathway exists in E. coli), while the
CYH reaction can also occur spontaneously. However, carolacton
is effluxed in wt E. coli as evidenced by the activity on E. coli
ΔtolC mutants, and the data show a strong enhancing effect of
the efflux pump inhibitor PAβN.
Due to the high degree of sequence conservation between FolD
and human mitochondrial hsMTHFD2, especially of the key
carolacton-binding residues, we tested carolacton as a possible
inhibitor of hsMTHFD2. This protein is overexpressed in many
tumor cells20, and we observed strong inhibition and binding by
carolacton in vitro. To see if carolacton could serve as a starting
point for FolD/hsMTHFD2 inhibitors that display activity on
whole cells, we tested the effect of carolacton on several cancer
cell lines. Carolacton displayed moderate activity in these assays.
Since carolacton is able to inhibit both reactions carried out by
this enzyme and perturbs cofactor binding, we believe that car-
olacton, a non-substrate inhibitor, may be used as a tool com-
pound to assess MTHFD2 as an anti-cancer target in the future.
Methods
Strains and plasmids. The E. coliΔtolC strain used in carolacton-resistant mutant
development is an antibiotic-sensitive E. coli strain with deficient outer membrane
channel protein TolC. It was the same strain used in the previous carolacton
studies2, 4. E. coli DH10B35 or DH5α (Invitrogen) strains were used for gene
cloning and E. coli BL21 (DE3) (Novagen) was used for protein expression. E. coli
DSM-1116 was ordered from German Collection of Microorganisms and Cell
Cultures (DSMZ). The protein expression plasmid pHis-TEV36 was used for
cloning and expression of all folD gene orthologues studied in this paper (Sup-
plementary Table 9).
Carolacton-resistant mutant development. First, the minimum inhibitory con-
centration (MIC) of carolacton on the E. coliΔtolC strain was determined. We
started to develop the resistant mutants on CASO agar (peptone from casein 15 g/
L, peptone from soybean 5 g/L, NaCl 5 g/L and agar 15 g/L; pH 7.3) plates sup-
plemented with 4× the MIC concentration of carolacton (0.5 μg/mL) as selection
pressure. Different numbers of E. coliΔtolC cells from 1 × 107 to 109 were spread on
caso agar plates with carolacton. After 7 days, E. coliΔtolC colonies, which were
resistant to carolacton, started to form on the agar plates. The mutants picked were
inoculated in liquid MHB medium (beef extract 2 g/L, peptone from casein 17.5 g/L
and corn starch 1.5 g/L, pH 7.4) supplemented with carolacton. The genomic DNA
of wt E. coliΔtolC and five carolacton resistant mutants were extracted and
the genomes sequenced.
Whole-genome sequencing and variant calling. Genomic DNA of five inde-
pendent mutant strains and one control E. coli ΔtolC strain was sequenced using
Illumina Paired-End technology on the MiSeq instrument at the Helmholtz Centre
for Infection Research (Braunschweig, Germany). Characteristics of the obtained
raw-data sequencing reads are shown in Supplementary Table 1. Raw data were
imported into the Geneious 9.1.337 software package and trimmed of low-quality
parts with an error probability threshold of 0.05. It was aligned against the E. coli
ΔtolC reference sequence using the ‘Low sensitivity’ option of the Geneious ‘Map
to reference…’ sequence aligner. This produced assembly files in which whole
genome mean sequencing coverages varied in the range of 108–116. Assembly files
were then converted to consensus sequences by the ‘Generate consensus
sequence…’ option in the Geneious software and ‘Highest quality’ consensus
calling option. Six resulting consensus sequences were aligned to each other and to
the reference genome sequence by the ‘progressiveMauve’ algorithm of
the MAUVE whole-genome sequence alignment tool38. The variant calling was
done by comparing the consensus sequences of each mutant sample against the
control E. coli ΔtolC WT consensus sequence. The complete list of mutations is
shown in Supplementary Table 2.
Gene cloning and protein purification. All folD gene orthologues studied in this
paper were cloned into the pHis-TEV protein expression vector. The folD genes of
E. coliΔtolC and its carolacton-resistant mutants were amplified from the genomic
DNA of the corresponding strains. The folD gene of S. pneumoniae was amplified
from the genomic DNA of the TIGR4 strain39. The cDNAs encoding MTHFD1
and MTHFD2 were synthesized based on the available human genomic DNA
sequences (gene ID 4522 and 10197, respectively; DNA synthesized by ATG:bio-
synthesis). All primers and restriction sites are listed in Supplementary Table 10.
The resulting protein expression plasmids were verified by enzyme restriction
digestion and DNA sequencing before being transformed into E. coli BL21 (DE3)
for protein overexpression and purification. For optimal protein purification, a
systematic buffer test including ten different buffers was conducted for each protein
by using the KingFisher mL (ThermoFisher scientific) magnetic beads purification
system. For large-scale protein purification, a single colony was picked into LB
liquid medium containing 50 μg/mL kanamycin to make an overnight culture. The
overnight culture was inoculated 1 to 100 into fresh LB medium supplemented
with 50 μg/mL kanamycin and was grown at 37 °C until the optical density at 600
nm (OD600) reached 0.6. Then, the culture was transferred to 16 °C for half-an-
hour to cool the culture before 0.1 mM IPTG was added to induce protein
expression. The cells were harvested and lysed by sonication after 16 h shaking at
16 °C. The proteins were purified by immobilized metal ion affinity chromato-
graphy (IMAC) on a 5 mL Histrap HP column (GE healthcare). A HiPrep 26/10
desalting column (GE healthcare) was used to remove imidazole. When removal of
the N-terminal 6x His-tag was required, TEV protease was added to the imidazole
free protein solution and incubated at 4 °C overnight, followed by another hour at
room temperature. The digestion mixture was loaded on a HisTrap HP column for
a second time to bind the undigested protein, His-tag and TEV protease. The flow-
through, which contained the protein, was collected, concentrated and loaded onto
a gel filtration column HiLoad 16/600 Superdex 200 pg (GE healthcare) to further
remove impurities and FolD aggregates. Finally, all purified proteins used in this
study were checked by sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) and subjected to liquid chromatography–mass spectrometry (LC-MS)
to check purity and assess protein molecular weights. All buffers for protein
purification are listed in Supplementary Table 11.
Enzyme assay conditions. (6R,S)-5,10-Methylene-5,6,7,8-tetrahydrofolic acid
((6R,S)-5,10-CH2-THF) calcium salt and (6R,S)-5,10-Methenyl-5,6,7,8-tetra-
hydrofolic acid ((6R,S)-5,10-CH=THF) chloride were purchased from Schircks
Laboratories (Bauma, Switzerland) and used as substrates for FolD dehydrogenase
and cyclohydrolase enzyme assays, respectively. Only the R-isomer, which accounts
for 50% of (6R,S)-5,10-CH2-THF and (6R,S)-5,10-CH=THF, respectively, is used
by the enzyme. (6R,S)-5,10-CH2-THF was dissolved in N2-spargeled basic buffer
(50 mM Tris-HCl (pH 8.0), 100 mM β-mercaptoethanol) as described by Varshney
et al.25. (6R,S)-5,10-CH=THF was dissolved in DMSO as a 100 mM stock solution.
Because FolD is a bifunctional enzyme, dehydrogenase and cyclohydrolase
activities were determined for FolD enzyme kinetics, respectively. The
dehydrogenase activity of FolD was assayed for its substrate 5,10-CH2-THF and
cofactor NADP+ (in the case of MTHFD2, NAD+ was used as the cofactor) based
on monitoring the formation of 5,10-CH=THF, while the cyclohydrolase activity of
FolD was determined for its substrate 5,10-CH=THF by monitoring the hydrolysis
of 5,10-CH2-THF. The enzyme kinetics for the dehydrogenase activity of all FolDs
except hsMTHFD1_DC were determined at 30 °C in 50 mM Tris-HCl (pH 7.5), 30
mM β-mercaptoethanol. The hsMTHFD1_DC dehydrogenase activity was
measured in 25 mM MOPS (pH 7.3), 30 mM β-mercaptoethanol at 30 °C. To
measure the enzyme kinetic constants for 5,10-CH2-THF, for example in the case
of ecFolD, the NADP concentration was fixed at 1 mM and the concentration of
5,10-CH2-THF varied from 5 to 1500 μM (R-isomer). Similarly, to measure the
kinetic constants of ecFolD for NADP+, the concentration of 5,10-CH2-THF (R-
isomer) was fixed at 1 mM and the concentration of NADP+ varied from 10 to
1500 μM. For different FolDs, the varied concentration range of substrates could be
different. The 50 μL reactions of dehydrogenase assays were initiated by adding
appropriate amounts enzyme (4 nM ecFolD, 4 nM spFolD, 15 nM
hsMTHFD1_DC, 20 nM hsMTHFD2, 20 nM G8S, 20 nM Q98H, 10 nM K54N and
200 nM ΔK54R55 in the corresponding assays) and terminated with 50 μL 1M
HCl after 2 min incubation at 30 °C. To monitor the formation of 5,10-CH=THF,
the absorbance of the reaction mixture was monitored at 350 nm in micro UV
cuvettes (BRAND, Essex, Connecticut, USA). The concentration of 5,10-CH=THF
produced in the reaction was determined using an extinction co-efficient of 0.0249
μM−1 cm−1. Cyclohydrolase activity for each FolD was assayed in the same buffer
as dehydrogenase activity at 30 °C but for 30 s. The concentration of FolD used in
each assay was 5 nM of ecFolD, spFolD and hsMTHFD1_DC, respectively, and 2
nM of hsMTHFD2. The consumption of 5,10-CH=THF was measured by
recording the absorbance of the reactions at 355 nm using the TECAN Infinite 200
PRO equipped with a monochromator. To measure the enzyme kinetic constants,
different concentrations of 5,10-CH=THF (varied from 0.5 μM to 100 μM) were
used in 100 μL reaction mixtures. The inhibition constants (Ki) of carolacton on
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FolD were determined by measuring the apparent Km when adding certain
amounts of carolacton to the enzyme reactions. For ecFolD, 10 nM carolacton was
added in the dehydrogenase assay and 50 nM carolacton was used in the
cyclohydrolase assay. For spFolD, 25 nM carolacton was added in both
dehydrogenase assay and cyclohydrolase assay. For hsMTHFD1_DC, 30 nM
carolacton was added in the dehydrogenase assay and 10 nM in the cyclohydrolase
assay. For hsMTHFD2, 20 nM carolacton was used to determine the apparent Km
for 5,10-CH2-THF and 5,10-CH2-THF, while 10 nM carolacton was used to
determine the apparent Km for NADP. To compare the inhibition effects of
carolacton between the different FolDs, the half maximal inhibitory concentration
(IC50) of carolacton on the same amount of enzyme was determined for FolDs
involved in this study. The enzyme concentration used to determine
dehydrogenase activity IC50 was 10 nM, and the enzyme used for cyclohydrolase
IC50 measurements was 5 nM. All enzyme kinetics measurements were performed
as independent triplicates. Data processing and fitting of curves was done using
OriginPro 2016 (OriginLab, Northampton, Massachusetts, US). Analysis of
variance (ANOVA) in OriginPro 2016 software gave statistical test reports after
fitting curves.
Surface plasmon resonance assay. All surface plasmon resonance (SPR)
experiments described in this study were performed on a Biacore X100 system.
Different FolDs with or without His-tag were coupled on CM5 sensor chips (GE
Healthcare) by the amine coupling method using a kit from GE Healthcare Life
Sciences (Freiburg, Germany). A pH scouting process was performed before pro-
tein immobilization to test the most appropriate buffer and the protein con-
centration for protein coupling. Finally, 20 μg/mL of ecFolD in 10 mM maleate
buffer (pH 6.8), 30 μg/mL of ecFolD Q98H in 10 mM maleate buffer (pH 6.3), 40
μg/mL of ecFolD K54N in 10 mM maleate buffer (pH 5.8), 20 μg/mL of spFolD in
10 mM maleate buffer (pH 6.0) and 15 μg/mL of MTHFD2 (His-tag cleaved) in 10
mM maleate buffer (pH 6.8) were used for coupling. In the protein immobilization
procedure, the contact time was calculated based on the pH scouting results to
achieve ~3000–5000 relative resonance units (RU). The buffer used in the SPR
assays was 1× HBS-P buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 0.05% Tween
20). The 1 mM stock solution of carolacton was prepared in 1× HBS-P buffer and
diluted to different concentration ranges by two-fold serial dilution. In the SPR
assay, the association time was 180 s and the dissociation time was 600 s. Data
analysis was performed using the Biacore evaluation software. The SPR curves were
exported to be re-plotted in OriginPro 2016 (OriginLab, Northampton, Massa-
chusetts, US).
Antimicrobial screening. The determination of MICs was performed as described
elsewhere40. In brief, E. coli strains were treated with carolacton in serial dilution in
either the presence or absence of sub-inhibitory concentrations of polymyxin B
nonapeptide (PMBN; 3 µg/mL) and/or phenylalanine–arginine β-napthylamide
(PAβN; 20 µg/mL) for 16 h at 37 °C in Mueller–Hinton broth. The MICs were
assessed by visual inspection of the plates.
Cytotoxicity screening. Half maximal effective concentrations (EC50) on human
cancer cell lines were determined as described elsewhere41. Human cancer cell lines
were maintained as recommended by the depositor (German Collection of
Microorganisms and Cell Cultures, DSMZ) and were treated for 5 d with car-
olacton in serial dilution. The viability of adherent cell types, HCT-116 (ACC 581),
KB-3.1 (ACC-158) and KB-V.1 (ACC-149) was assessed by the addition of MTT
tetrazolium salt and absorbance measurement at 570 nm. Histiocytic lymphoma U-
937 cells (ACC-5) were maintained in RPMI 1640 medium and transferred into
folate-free medium prior to the assay. Cell viability was determined by measuring
alamar blue fluorescence emission at 590 nm. The values were referenced and EC50
values were determined by sigmoidal curve fitting. The cell lines KB-3.1 and KB-
V.1 are originally derived from HeLa, whereas the latter is an MDR subclone of
KB-3.1. They were used to directly compare the activity of carolacton on an mdr1
overexpressing and a sensitive cell line. The effect of folate depletion was assessed
using the U-937 cell line as these lymphoma cells are described to express high
levels of MTHFD2, however, carolacton was virtually inactive under normal cul-
ture conditions.
Reductive methylation of surface lysine residues. To protect active site lysine
K54, a six-fold molar excess of carolacton was added to the protein and the
complex incubated on ice for 16 h before the reaction. Surface lysine residues were
then methylated using the JBS Methylation Kit (Jena Bioscience) according to the
manufacturer’s instructions and Supplementary Information. Methylated ecFolD
(ecFolDMeth) and ecFolDMethQ98H were applied to a Superdex 200 gel filtration
column (GE Healthcare) pre-equilibrated with gel filtration buffer (150 mM NaCl,
10 mM HEPES (pH 7.4) and 1 mM TCEP), and then concentrated to 5 mg/mL.
X-ray crystallography. Crystals of ecFolDMeth were obtained at 18 °C by using the
sitting drop vapour diffusion method. Protein (300 nL) at 5 mg/mL was added to
150 nL reservoir solution: 0.2 M sodium acetate, 0.1 M sodium cacodylate pH 6.5
and 30% (w/v) PEG 8000. To solve the ecFolD-carolacton complex structure,
ecFolDMeth crystals were soaked overnight in the presence 2 mM carolacton.
Optimized crystals of apo-ecFolDMethQ98H were grown under conditions of 0.2
ammonium sulphate, Bis-Tris pH 6.0 and 25% PEG 3350. Diffraction data for all
proteins were collected from single crystals at 100 K. Data for ecFolDMeth were
obtained at Beamline X06DA at a wavelength of 1 Å (Swiss Light Source), while
data for the ecFolDMeth–carolacton complex and ecFoldMethQ98H crystals were
collected at beamline ID30-A3 (ESRF) at a wavelength of 0.967 Å. Data were
processed using Xia242 or XDS43 and the structures solved using PHASER44
Molecular replacement with ecFolD (PDB ID 1DIA) as a search model. The models
were manually rebuilt in COOT45 and refined using PHENIX46 and Refmac547
(Supplementary Table 12). The structures were validated using MolProbity, and all
images presented were created using PyMOL48. Interaction diagrams were created
using Ligplot49.
Data availability. Atomic coordinates and structure factors are deposited in the
RCSB Protein Data Bank with accession codes 5O28 (ecFolD apo), 5O22 (ecFolD
carolacton complex) and 5O2A (ecFolDQ98H). Other relevant data supporting the
findings of this study are available in this published article and its Supplementary
Information files or from the corresponding authors upon request.
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